MX2024009923A - Metodos para tratar el cancer de prostata. - Google Patents
Metodos para tratar el cancer de prostata.Info
- Publication number
- MX2024009923A MX2024009923A MX2024009923A MX2024009923A MX2024009923A MX 2024009923 A MX2024009923 A MX 2024009923A MX 2024009923 A MX2024009923 A MX 2024009923A MX 2024009923 A MX2024009923 A MX 2024009923A MX 2024009923 A MX2024009923 A MX 2024009923A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- methods
- treating prostate
- subject
- disclosure
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 4
- 229960004103 abiraterone acetate Drugs 0.000 abstract 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229960000572 olaparib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268026P | 2022-02-15 | 2022-02-15 | |
| PCT/EP2023/053555 WO2023156357A1 (en) | 2022-02-15 | 2023-02-14 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009923A true MX2024009923A (es) | 2024-08-22 |
Family
ID=85283519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009923A MX2024009923A (es) | 2022-02-15 | 2023-02-14 | Metodos para tratar el cancer de prostata. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250134887A1 (https=) |
| EP (1) | EP4479053A1 (https=) |
| JP (1) | JP2025505041A (https=) |
| KR (1) | KR20240148418A (https=) |
| CN (1) | CN118829430A (https=) |
| AU (1) | AU2023220646A1 (https=) |
| CA (1) | CA3250763A1 (https=) |
| IL (1) | IL314798A (https=) |
| MX (1) | MX2024009923A (https=) |
| TW (1) | TW202400267A (https=) |
| WO (1) | WO2023156357A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
-
2023
- 2023-02-14 CN CN202380021612.6A patent/CN118829430A/zh active Pending
- 2023-02-14 US US18/837,956 patent/US20250134887A1/en active Pending
- 2023-02-14 EP EP23705969.6A patent/EP4479053A1/en active Pending
- 2023-02-14 WO PCT/EP2023/053555 patent/WO2023156357A1/en not_active Ceased
- 2023-02-14 IL IL314798A patent/IL314798A/en unknown
- 2023-02-14 MX MX2024009923A patent/MX2024009923A/es unknown
- 2023-02-14 JP JP2024547679A patent/JP2025505041A/ja not_active Withdrawn
- 2023-02-14 AU AU2023220646A patent/AU2023220646A1/en active Pending
- 2023-02-14 CA CA3250763A patent/CA3250763A1/en active Pending
- 2023-02-14 KR KR1020247030614A patent/KR20240148418A/ko not_active Withdrawn
- 2023-02-15 TW TW112105268A patent/TW202400267A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250134887A1 (en) | 2025-05-01 |
| EP4479053A1 (en) | 2024-12-25 |
| WO2023156357A1 (en) | 2023-08-24 |
| TW202400267A (zh) | 2024-01-01 |
| KR20240148418A (ko) | 2024-10-11 |
| CN118829430A (zh) | 2024-10-22 |
| JP2025505041A (ja) | 2025-02-19 |
| IL314798A (en) | 2024-10-01 |
| CA3250763A1 (en) | 2023-08-24 |
| AU2023220646A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| MX2016017288A (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| MX2023002076A (es) | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| BR112017028530A2 (pt) | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos | |
| MX2019001224A (es) | Metodos para tratar el cancer de prostata. | |
| CY1122541T1 (el) | Συνδυαστικη θεραπεια καρκινου | |
| BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| MX2022010512A (es) | Inhibidores de proteína bcl-2. | |
| MX2014004646A (es) | Metodo para inhibicion de actividad desubiquitinante. | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| MX2019013862A (es) | Terapia de combinacion. | |
| BR112019024719A2 (pt) | Composições e métodos para resposta imunológica antitumor aprimorada | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| MX2020003830A (es) | Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos. | |
| PH12017501881A1 (en) | Methods for treating cancer | |
| JOP20220288A1 (ar) | علاج سرطان البروستات بتوليفة من أبيراتيرون أسيتات ونيراباريب | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. |